Bioabsorbable Drug-Eluting Stent Treats Coronary Artery Disease

The proprietary PLGA polymer completes absorption shortly after everolimus drug elution ends (at three months), leaving only the bare platinum chromium stent.

The platinum chromium alloy and enhanced stent design enable thinner struts and improved deliverability while maintaining excellent conformability, flexibility, radiopacity, and low recoil. The technology provides the same level of restenosis reduction as a conventional everolimus-eluting stent, while offering faster and more complete vessel healing after implantation, potentially reducing duration of post-procedure dual antiplatelet therapy. The SYNERGY BP-DES is a product of Boston Scientific (Natick, MA, USA) and has been approved by the US Food and Drug Administration (FDA).

“In addition to its innovative coating, the foundation of the SYNERGY stent is our proprietary platinum chromium alloy and an enhanced stent design which allow for thinner struts, increased visibility and an extremely low crossing profile for easier deliverability,” said Kevin Ballinger, president of interventional cardiology at Boston Scientific. “The SYNERGY stent is a next generation therapy designed to improve patient outcomes and ultimately reduce health care costs associated with the treatment of coronary artery disease.”

Long-term exposure to polymer may cause inflammation, which delays healing and has been associated with other complications, including neoatherosclerosis and stent thrombosis.

Related Links:
Boston Scientific